Smith & Nephew/£SN

07:00
03:10
23:15
19:25
15:30
1D1W1MYTD1Y5YMAX

About Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Ticker

£SN

Primary listing

LSE

Industry

Health Care Equipment and Supplies

Employees

17,349

Smith & Nephew Metrics

BasicAdvanced
£10B
33.61
£0.35
0.63
£0.29
2.44%

What the Analysts think about Smith & Nephew

Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.

Bulls say / Bears say

Smith & Nephew's strategic partnership with Standard Health to establish the UK's first dedicated Orthopaedic Ambulatory Surgery Centre positions the company to capitalize on the growing shift toward outpatient orthopedic procedures, potentially enhancing revenue and market share. (nasdaq.com)
The company's first-quarter 2025 results showed a 3.1% year-over-year revenue growth, indicating operational improvements and sustained demand for its products. (massdevice.com)
Smith & Nephew's stock reached a 52-week high of $31.25 in September 2024, reflecting strong investor confidence and positive market sentiment. (investing.com)
JPMorgan Chase & Co. significantly reduced its position in Smith & Nephew by 90.5% during the third quarter, which may indicate concerns about the company's future performance. (defenseworld.net)
Several analysts, including UBS Group and HSBC, downgraded Smith & Nephew's stock from 'buy' to 'hold' in early 2025, suggesting a more cautious outlook on the company's growth prospects. (defenseworld.net)
The company's exposure to foreign exchange headwinds and market volatility, as noted in their first-quarter 2025 report, could impact profitability and financial stability. (massdevice.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Smith & Nephew Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Smith & Nephew Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £SN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs